Skip to main content

PROC

Stock
Health Care
Drug Manufacturers - Specialty & Generic

Performance overview

PROC Price
Price Chart

Forward-looking statistics

Beta
0.13
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Procaps Group SA is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and high-potency clinical solutions. The company's segment includes NextGel; Procaps Colombia; CAN; CASAND and Diabetrics. It generates maximum revenue from the Procaps Colombia segment.

Company info

SectorHealth Care
IndustryDrug Manufacturers - Specialty & Generic
Employees6K
Market cap$296.7M

Fundamentals

Enterprise value$403.8M
Revenue$414.1M
Revenue per employee—
Profit margin12.61%
Debt to equity753.94

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$0.66
Dividend per share—
Revenue per share$4.10
Avg trading volume (30 day)$188
Avg trading volume (10 day)$272
Put-call ratio—

Macro factor sensitivity

Growth-4.1
Credit-5.7
Liquidity+5.4
Inflation-2.1
Commodities-2.5
Interest Rates-0.5

Valuation

Dividend yield0.00%
PEG Ratio3.74
Price to sales0.28
P/E Ratio3.74
Enterprise Value to Revenue0.97
Price to book2.59

Upcoming events

Next earnings dayJune 6, 2023
Next dividend day—
Ex. dividend day—

News

Procaps Group, S.A. (PROC) Q3 Earnings and Revenues Top Estimates

Procaps Group, S.A. (PROC) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.05 per share.

Zacks Investment Research (December 27, 2023)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free